Correlation between serum sCD40L and sCD40 levels with disease progression and plaque property change in patients with ACS

摘要

Objective:To study the relationship of serum soluble CD40 (sCD40), soluble CD40 ligand (sCD40L) levels with disease progression and plaque property change in patients with acute coronary syndrome (ACS). Methods:156 patients diagnosed with acute coronary syndrome in our hospital between May 2014 and December 2015 were selected as the ACS group of the study, and 60 healthy volunteers receiving physical examination in our hospital during the same period were selected as the control group of the study. Serum was collected to determine the levels of sCD40L, sCD40 as well as inflammation-related factors and plaque stability-related molecules. Results:Serum sCD40 and sCD40L levels of ACS group were significantly higher than those of control group (P<0.05), serum sCD40 and sCD40L levels of non-ST-elevation myocardial infarction (NSTEMI) patients and ST-elevation myocardial infarction (STEMI) patients in ACS group were significantly higher than those of UAP group (P<0.05), and serum sCD40 and sCD40L levels of STEMI patients were significantly higher than those of NSTEMI patients (P<0.05);serum inflammation-related factors hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-8 (IL-8) and IL-18 as well as plaque stability-related molecules matrix metalloproteinase 2 (MMP2), MMP9, lysophosphatide acid (LPA) and angiopoietin-like protein 2 (Angptl2) levels of ACS group were significantly higher than those of control group (P<0.05) and positively correlated with sCD40L and sCD40 levels. Conclusions:Serum sCD40L and sCD40 levels abnormally increase in patients with ACS and are closely related to the inflammatory cascade activation and plaque property change during disease progression.